Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM

Keyphrases

• Hypertrophic Obstructive Cardiomyopathy 100%
• Aficamten 100%
• Left Ventricular Ejection Fraction 25%
• Cardiac Biomarkers 25%
• Left Ventricular Outflow Tract Gradient 25%
• Valsalva 25%
• Symptom Burden 12%
• Placebo 12%
• Tolerability 12%
• Research Evaluation 12%
• Long-term Efficacy 12%
• Cardiomyopathy 12%
• Hypertrophic Cardiomyopathy 12%
• Substantial Reduction 12%
• Once-daily 12%
• Safety Data 12%
• Dose Finding 12%
• Long-term Safety 12%
• Echocardiographic Evaluation 12%
• Efficacy Data 12%
• Cardiac Remodeling 12%
• Drug Discontinuation 12%
• Phenotypic Change 12%
• Left Atrial Volume Index 12%
• Open-label Extension 12%
• Class Improvement 12%
• Left Ventricular Wall Thickness 12%
• New-onset Atrial Fibrillation 12%
• Kansas City 12%
• NYHA Functional Class 12%
• Mg-based Materials 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Hypertrophic Obstructive Cardiomyopathy 100%
• Biological Marker 50%
• Tolerability 25%
• Placebo 25%
• Heart Ventricle Remodeling 25%
• Heart Ventricle Hypertrophy 25%
• Myocardial Disease 25%
• Hypertrophic Cardiomyopathy 25%
• Obstruction 25%
• New-Onset Atrial Fibrillation 25%

Medicine and Dentistry

• Left Atrial Volume 25%